{"schema":"hottub-news/story/v1","story":"st_wcsmnwbnpdupxapsj54a","title":"Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND","title_en":null,"outlets":3,"brief":null,"page":"https://hottub.news/stories/ernexa-therapeutics-reports-compelling-erna-101-safety-results-across-wcsmnwbnpd","count":3,"items":[{"id":"n_pzidyidlmdftrvmgfixq","seq":921500,"kind":"article","title":"Ernexa Therapeutics Advances ERNA-101 Toward Planned Q4 2026 IND","url":"https://www.rttnews.com/3695374/ernexa-therapeutics-advances-erna-101-toward-planned-q4-2026-ind.aspx","published":"2026-09-30T13:40:00Z","seen":"2026-09-30T14:09:34Z","lang":"en","source":{"id":"rttnews.com","name":"rttnews.com","domain":"rttnews.com","outlet":{"wikidata":"Q60748698","name":"RTTNews","type":"news_agency","designations":["news agency","news website"]}},"via":"gdelt-gkg-english","topics":["economy"],"story":"st_wcsmnwbnpdupxapsj54a","category":"economy-business","category_p":0.41999998688697815,"category2":"health","sentiment":"positive","tone":0.019999999552965164,"political":0.029999999329447746},{"id":"n_et7hmsbejle5psjc4haq","seq":912552,"kind":"article","title":"Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND","url":"https://www.manilatimes.net/2026/09/30/tmt-newswire/globenewswire/ernexa-therapeutics-reports-compelling-erna-101-safety-results-across-three-critical-ind-enabling-studies-advancing-toward-planned-q4-2026-ind/2436102","published":"2026-09-30T12:41:00Z","seen":"2026-09-30T13:17:34Z","lang":"en","source":{"id":"manilatimes.net","name":"manilatimes.net","domain":"manilatimes.net","outlet":{"wikidata":"Q1573100","name":"The Manila Times","type":"magazine","country":"PH","designations":["organization","periodical"]}},"via":"gdelt-gkg-english","topics":["politics","economy","health","science"],"entities":[{"id":"Q12277","name":"arch","type":"org"}],"story":"st_wcsmnwbnpdupxapsj54a","category":"health","category_p":0.4399999976158142,"category2":"economy-business","sentiment":"positive","tone":0.10999999940395355,"political":0.03999999910593033},{"id":"n_wcsmnwbnpdupxapsj54a","seq":901285,"kind":"press_release","title":"Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND","url":"https://www.globenewswire.com/news-release/2026/09/30/3371881/0/en/ernexa-therapeutics-reports-compelling-erna-101-safety-results-across-three-critical-ind-enabling-studies-advancing-toward-planned-q4-2026-ind.html","summary":"Repeat-dose GLP toxicology study showed no ERNA-101-related adverse findings across all dose levels tested, including no clinical pathology or histopathology findings; single-dose assessment showed no evidence of acute cytokine release","published":"2026-09-30T12:32:00Z","seen":"2026-09-30T12:37:48Z","lang":"en","source":{"id":"globenewswire-public","name":"GlobeNewswire — public companies","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-public","topics":["business","nasdaq:erna","us1140822099"],"image":"https://ml.globenewswire.com/Resource/Download/912c23d8-20bf-4df7-8861-e63dcd5874fd","story":"st_wcsmnwbnpdupxapsj54a","category":"health","category_p":0.4399999976158142,"category2":"economy-business","sentiment":"positive","tone":0.4000000059604645,"political":0.03999999910593033}]}